119th Congress · House bill · Last action Sep 19, 2025
H.R. 5526In CommitteeHealth
Republicans seek to reduce biosimilar drug approval regulations.
Sponsor: Rep. Pfluger, August (R-TX)10 cosponsorsIntroduced Sep 19, 2025
✆
In plain English
A plain-English summary isn’t available for this bill yet.
Where it is in the process
✓
Introduced
Sep 19
✓
House committee
Sep 19
3
House floor
-
4
Senate
-
5
Signed
-
What happens next: Sits in committee. Needs a markup or favorable report to advance to the House floor.
Community vote
How readers of ThePolitibase feel about this bill. Reader sentiment only — not a scientific poll, and not a measure of public opinion.
- support · - oppose · - total
Sponsor
AR
Cosponsors (10)
GR
JR
DR
GR
BR
RR
BR
+3
4 Democrats, 6 Republicans (of 10 shown).
Activity timeline
Sep 19
Sep 19, 2025
Sep 19, 2025
Referred to the House Committee on Energy and Commerce.
Sep 19
Sep 19, 2025
Sep 19, 2025
Introduced in House
Sep 19
Sep 19, 2025
Sep 19, 2025
Introduced in House
Read the bill text
Official text via Congress.gov. Opens in a new tab.
Full action log
All 3 recorded actions since introduction · Source: Congress.gov
Sep 19
HOUSEReferred to the House Committee on Energy and Commerce.
Sep 19
Introduced in House
Sep 19
Introduced in House
All 10 cosponsors
4 Democrats · 6 Republicans
Democrats (4)
Republicans (6)
Crenshaw, DanTX-02
Owens, BurgessUT-04
Fine, RandyFL-06
Moore, Blake D.UT-01
Goldman, Craig A.TX-12
Wittman, Robert J.VA-01
In the news
Track this bill
Get an alert when it moves to the next stage or gets a vote.